BridgeBio Oncology Therapeutics, Inc. (BBOT)
NASDAQ: BBOT · Real-Time Price · USD
8.56
+0.25 (3.01%)
Jul 17, 2026, 4:00 PM EDT - Market closed
BBOT Stock Forecast
Stock Price Forecast
According to 11 analysts polled by S&P Global, BBOT stock has a consensus rating of "Strong Buy" and an average price target of $25.3. The average 1-year stock price forecast is 195.56% higher than the current stock price, while the lowest is $18 (+110.28%) and the highest is $41 (+378.97%).
Price Target: $25.3 (+195.56%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for BBOT stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 6 | 6 | 6 | 7 | 7 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 9 | 9 | 9 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
Unknown Analyst J.P. Morgan No rating | J.P. Morgan | Buy Initiates $27 | Buy | Initiates | $27 | +215.42% | Jul 8, 2026 |
| Canaccord Genuity | Canaccord Genuity | Buy Maintains $23 | Buy | Maintains | $23 | +168.69% | Jul 8, 2026 |
| Oppenheimer | Oppenheimer | Buy Initiates $22 | Buy | Initiates | $22 | +157.01% | Jun 22, 2026 |
| Piper Sandler | Piper Sandler | Buy Maintains $21 | Buy | Maintains | $21 | +145.33% | Jun 1, 2026 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $18 | Buy | Maintains | $18 | +110.28% | May 15, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-2.21
from -4.30
EPS Next Year
-2.11
from -2.21
EPS and Forward PE are based on non-GAAP adjusted numbers.